Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Toripalimab in Platinum-Resistant Recurrent Ovarian Cancer
NCT06241105Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, toripalimab in ovarian cancer, sponsored by Peking Union Medical College Hospital. Started Feb 2023; status: recruiting.
02
Drugs
lenvatinibtoripalimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06241105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241105.